Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Could CT scans be fueling a future rise in cancer cases, as a new study suggests?

2.

recognizing the mechanism by which the replication of the host cell is outperformed by the skin cancer virus.

3.

Clinical trial is testing whether heavy lifting could combat cancer side effects

4.

By acquiring T3 Pharma, a leader in bacterial cancer treatment, Boehringer Ingelheim broadens its offering in immunooncology.

5.

Dual-action mRNA vaccine takes aim at aggressive skin cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot